Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens.

Smith NL, Blondon M, Wiggins KL, Harrington LB, van Hylckama Vlieg A, Floyd JS, Hwang M, Bis JC, McKnight B, Rice KM, Lumley T, Rosendaal FR, Heckbert SR, Psaty BM.

JAMA Intern Med. 2014 Jan;174(1):25-31. doi: 10.1001/jamainternmed.2013.11074. Erratum in: JAMA Intern Med. 2014 Sep;174(9):1523.

2.

Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.

Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM.

JAMA. 2004 Oct 6;292(13):1581-7.

PMID:
15467060
3.

Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke.

Lemaitre RN, Weiss NS, Smith NL, Psaty BM, Lumley T, Larson EB, Heckbert SR.

Arch Intern Med. 2006 Feb 27;166(4):399-404.

PMID:
16505258
4.

Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers.

Blondon M, van Hylckama Vlieg A, Wiggins KL, Harrington LB, McKnight B, Rice KM, Rosendaal FR, Heckbert SR, Psaty BM, Smith NL.

J Thromb Haemost. 2014 Jun;12(6):879-86. doi: 10.1111/jth.12560.

5.

The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.

Roach RE, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A.

J Thromb Haemost. 2013 Jan;11(1):124-31. doi: 10.1111/jth.12060.

6.

A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.

Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ.

Ann Intern Med. 2000 Dec 19;133(12):933-41.

PMID:
11119394
7.

Transdermal hormone therapy and the risk of stroke and venous thrombosis.

Speroff L.

Climacteric. 2010 Oct;13(5):429-32. doi: 10.3109/13697137.2010.507111.

PMID:
20670199
8.

Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study.

Shufelt CL, Merz CN, Prentice RL, Pettinger MB, Rossouw JE, Aroda VR, Kaunitz AM, Lakshminarayan K, Martin LW, Phillips LS, Manson JE.

Menopause. 2014 Mar;21(3):260-6. doi: 10.1097/GME.0b013e31829a64f9.

9.

The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.

Smith NL, Heckbert SR, Doggen CJ, Lemaitre RN, Reiner AP, Lumley T, Meijers JC, Psaty BM, Rosendaal FR.

J Thromb Haemost. 2006 Aug;4(8):1701-6.

10.

Estrogen plus progestin and risk of venous thrombosis.

Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR; Women's Health Initiative Investigators.

JAMA. 2004 Oct 6;292(13):1573-80.

PMID:
15467059
11.

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.

LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators.

JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382.

12.

Bioidentical hormones for women with vasomotor symptoms.

Gaudard AM, Silva de Souza S, Puga ME, Marjoribanks J, da Silva EM, Torloni MR.

Cochrane Database Syst Rev. 2016 Aug 1;(8):CD010407. doi: 10.1002/14651858.CD010407.pub2. Review.

PMID:
27479272
13.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee.

JAMA. 2004 Apr 14;291(14):1701-12.

14.

Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial.

Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, Køber L, Jensen JE.

BMJ. 2012 Oct 9;345:e6409. doi: 10.1136/bmj.e6409.

PMID:
23048011
15.

Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations.

Schneider C, Jick SS, Meier CR.

Climacteric. 2009 Oct;12(5):445-53. doi: 10.1080/13697130902780853.

PMID:
19565370
16.

[Basic principles of hormone replacement therapy in the postmenopause].

Dören M.

Ther Umsch. 2000 Oct;57(10):628-34. Review. German.

PMID:
11081374
17.

Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women.

Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Rosendaal FR, Psaty BM.

Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2807-12. Epub 2006 Sep 14.

PMID:
16973976
18.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.

Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee.

Endocr Pract. 2017 Jul;23(7):869-880. doi: 10.4158/EP171828.PS. Erratum in: Endocr Pract. 2017 Dec;23 (12 ):1488.

PMID:
28703650
19.
20.

Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women.

Sidney S, Petitti DB, Quesenberry CP Jr.

Ann Intern Med. 1997 Oct 1;127(7):501-8.

PMID:
9313017

Supplemental Content

Support Center